2X-121 for Ovarian Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Ovarian Cancer2X-121 - Drug
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial will test the effectiveness of 2X-121, given as a pill once daily, as a treatment for ovarian cancer in patients predicted to respond well to the drug.

Eligible Conditions
  • Ovarian Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: evaluated after up to approximately 2 years

Year 2
Quality of Life measurement
Year 2
Clinical benefit rate (CBR)
Correlation between 2X-121 DRP® and clinical outcome
Duration of response
Objective response rate (ORR)
Overall survival
Progression free survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

2X-121
1 of 1

Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: 2X-121 · No Placebo Group · Phase 2

2X-121Experimental Group · 2 Interventions: 2X-121, 2X-121 DRP® · Intervention Types: Drug, Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: evaluated after up to approximately 2 years

Who is running the clinical trial?

Allarity TherapeuticsLead Sponsor
7 Previous Clinical Trials
268 Total Patients Enrolled
1 Trials studying Ovarian Cancer
60 Patients Enrolled for Ovarian Cancer
Amarex Clinical ResearchOTHER
23 Previous Clinical Trials
1,542 Total Patients Enrolled
1 Trials studying Ovarian Cancer
60 Patients Enrolled for Ovarian Cancer
Alcedis GmbHIndustry Sponsor
6 Previous Clinical Trials
521 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be between the ages of 18 and 50 years.
A 2X-121 DRP® using Fixed in Formalin and Embedded in Paraffin (FFPE) archival or the latest tumor tissue with an outcome measured as being in the upper 50% likelihood of response.
You have a performance status of ECOG ≤ 1.
You have an absolute neutrophil count of at least 2.5 x 10/L.